Bioporto AS (OCSE:BIOPOR) Piotroski F-Score: 4 (As of Jun. 30, 2026) — 33% Above Median


OCSE:BIOPOR Bioporto AS OCSE:BIOPOR
69 GF Score
Price kr1.10
GF Value kr1.24
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bioporto AS Piotroski F-Score?

Bioporto AS OCSE:BIOPOR -0.45% 69 Piotroski F-Score is 4 as of Jun. 30, 2026, which is 33% above its 10-year median of 3.00. GuruFocus rates OCSE:BIOPOR with a GF Score™ of 69/100 and a GF Value™ of kr1.24 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Bioporto AS ranks worse than 51.43% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Bioporto AS has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Bioporto AS's Piotroski F-Score or its related term are showing as below:

OCSE:BIOPOR' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 5
Current: 4

During the past 13 years, the highest Piotroski F-Score of Bioporto AS was 5. The lowest was 2. And the median was 3.

Bioporto AS  (OCSE:BIOPOR) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Bioporto AS Piotroski F-Score Related Terms


Bioporto AS Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Bioporto AS's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioporto AS Piotroski F-Score Chart

Bioporto AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 5.00 3.00 3.00 4.00

Bioporto AS Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 1.00 0.00 1.00 4.00

OCSE:BIOPOR vs TMO, DHR, IDXX: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Bioporto AS's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioporto AS Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Bioporto AS's Piotroski F-Score falls into.


OCSE:BIOPOR
69GF Score
Bioporto AS OCSE:BIOPOR
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was -27.458 + -18.064 + -23.313 + -13.282 = kr-82.12 Mil.
Cash Flow from Operations was -24.106 + -17.055 + -20.228 + -15.677 = kr-77.07 Mil.
Revenue was 7.667 + 10.591 + 10.406 + 11.623 = kr40.29 Mil.
Gross Profit was 4.908 + 7.061 + 7.7 + 10.723 = kr30.39 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(95.984 + 74.669 + 88.035 + 68.09 + 93.182) / 5 = kr83.992 Mil.
Total Assets at the begining of this year (Dec24) was kr95.98 Mil.
Long-Term Debt & Capital Lease Obligation was kr4.05 Mil.
Total Current Assets was kr84.96 Mil.
Total Current Liabilities was kr26.12 Mil.
Net Income was -13.553 + -15.843 + -20.886 + -17.961 = kr-68.24 Mil.

Revenue was 9.461 + 9.2 + 9.685 + 7.897 = kr36.24 Mil.
Gross Profit was 7.17 + 6.983 + 6.682 + 3.695 = kr24.53 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(89.811 + 71.442 + 131.535 + 108.898 + 95.984) / 5 = kr99.534 Mil.
Total Assets at the begining of last year (Dec23) was kr89.81 Mil.
Long-Term Debt & Capital Lease Obligation was kr7.85 Mil.
Total Current Assets was kr83.90 Mil.
Total Current Liabilities was kr20.39 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Bioporto AS's current Net Income (TTM) was -82.12. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Bioporto AS's current Cash Flow from Operations (TTM) was -77.07. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-82.117/95.984
=-0.855528

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-68.243/89.811
=-0.75985124

Bioporto AS's return on assets of this year was -0.855528. Bioporto AS's return on assets of last year was -0.75985124. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Bioporto AS's current Net Income (TTM) was -82.12. Bioporto AS's current Cash Flow from Operations (TTM) was -77.07. ==> -77.07 > -82.12 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=4.049/83.992
=0.04820697

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=7.846/99.534
=0.07882734

Bioporto AS's gearing of this year was 0.04820697. Bioporto AS's gearing of last year was 0.07882734. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=84.958/26.124
=3.25210534

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=83.899/20.388
=4.11511674

Bioporto AS's current ratio of this year was 3.25210534. Bioporto AS's current ratio of last year was 4.11511674. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Bioporto AS's number of shares in issue this year was 495.096. Bioporto AS's number of shares in issue last year was 429.831. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=30.392/40.287
=0.75438727

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=24.53/36.243
=0.67682035

Bioporto AS's gross margin of this year was 0.75438727. Bioporto AS's gross margin of last year was 0.67682035. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=40.287/95.984
=0.4197262

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=36.243/89.811
=0.40354745

Bioporto AS's asset turnover of this year was 0.4197262. Bioporto AS's asset turnover of last year was 0.40354745. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Bioporto AS has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Bioporto AS (OCSE:BIOPOR) has a Piotroski F-Score of 4 as of Jun. 30, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Bioporto AS and its competitors. This is 33% above median its historical median of 3.00. Over the past decade, Bioporto AS's Piotroski F-Score has ranged from 2.00 to 5.00. According to the industry distribution chart, Bioporto AS ranks #108 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 51.4%.
Is Bioporto AS's Piotroski F-Score too high?
Bioporto AS's current Piotroski F-Score of 4 is 33% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 5.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Bioporto AS's value of 4 is 20% below this industry median. Based on the distribution chart, Bioporto AS ranks #108 out of 210 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Bioporto AS has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #108 out of 210 companies for Piotroski F-Score. This places Bioporto AS in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Bioporto AS's value of 4 is 20% below this benchmark. Historically, Bioporto AS's own Piotroski F-Score has ranged from 2.00 to 5.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, Bioporto AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioporto AS's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current Piotroski F-Score is 4, which is 33% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Based on GuruFocus' analysis, Bioporto AS (OCSE:BIOPOR) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.24, compared to a current price of kr1.10 — trading 11.3% below its estimated fair value. The current Piotroski F-Score is 4, which is 33% above median its 10-year median of 3.00 and 20% below the Medical Diagnostics & Research industry median of 5.00. Bioporto AS's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Bioporto AS (OCSE:BIOPOR), the current Piotroski F-Score is 4 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioporto AS (OCSE:BIOPOR) Overvalued in 2026?

Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued. The current stock price of kr1.10 is trading 11.3% below its estimated GF Value™ of kr1.24. GuruFocus considers Bioporto AS to be Modestly Undervalued.

Key valuation signals for OCSE:BIOPOR:

  • Piotroski F-Score: 4 (33% above median its 10-year median of 3.00)
  • GF Value™: kr1.24 vs. price of kr1.10 (11.3% below fair value)
  • GF Score™: 69/100 with 3 warning signs
  • Industry Position: 20% below the Medical Diagnostics & Research median (#108 of 210)

No single metric tells the full story. See the OCSE:BIOPOR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bioporto AS Business Description

Address Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
69GF Score

Get the complete analysis for OCSE:BIOPOR

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.10
Price
kr1.24
GF Value